BTIG Research Raises Establishment Labs (NASDAQ:ESTA) Price Target to $65.00

Establishment Labs (NASDAQ:ESTA) had its price objective lifted by BTIG Research from $62.00 to $65.00 in a report issued on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the stock. Citigroup raised their target price on shares of Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. cut their price objective on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Finally, Stephens reiterated an “overweight” rating and issued a $68.00 target price on shares of Establishment Labs in a research report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $58.83.

Establishment Labs Trading Down 1.4 %

Shares of ESTA stock opened at $42.29 on Monday. The firm has a market capitalization of $1.16 billion, a PE ratio of -13.47 and a beta of 1.20. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. The stock has a fifty day simple moving average of $42.93 and a two-hundred day simple moving average of $46.63. Establishment Labs has a 52-week low of $16.96 and a 52-week high of $60.12.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The business had revenue of $44.12 million during the quarter, compared to analysts’ expectations of $43.10 million. During the same period in the prior year, the firm posted ($0.65) earnings per share. The firm’s revenue for the quarter was down 9.2% on a year-over-year basis. On average, analysts predict that Establishment Labs will post -2.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently made changes to their positions in ESTA. Stableford Capital II LLC purchased a new stake in Establishment Labs in the 1st quarter worth about $1,568,000. BNP Paribas Financial Markets lifted its stake in shares of Establishment Labs by 32,968.7% during the 1st quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company’s stock worth $4,949,000 after acquiring an additional 96,928 shares during the last quarter. Swiss National Bank boosted its holdings in Establishment Labs by 13.6% during the 1st quarter. Swiss National Bank now owns 37,500 shares of the company’s stock valued at $1,909,000 after acquiring an additional 4,500 shares during the period. Concurrent Investment Advisors LLC bought a new position in Establishment Labs in the 1st quarter valued at $263,000. Finally, William Blair Investment Management LLC purchased a new stake in Establishment Labs in the first quarter worth $21,415,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.